miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling

Cristina Migliore, Elena Morando, Elena Ghiso, Sergio Anastasi, Vera P Leoni, Maria Apicella, Davide Cora', Anna Sapino, Filippo Pietrantonio, Filippo De Braud, Amedeo Columbano, Oreste Segatto, Silvia Giordano

Research output: Contribution to journalArticle

Abstract

The onset of secondary resistance represents a major limitation to long-term efficacy of target therapies in cancer patients. Thus, the identification of mechanisms mediating secondary resistance is the key to the rational design of therapeutic strategies for resistant patients. MiRNA profiling combined with RNA-Seq in MET-addicted cancer cell lines led us to identify the miR-205/ERRFI1 (ERBB receptor feedback inhibitor-1) axis as a novel mediator of resistance to MET tyrosine kinase inhibitors (TKIs). In cells resistant to MET-TKIs, epigenetically induced miR-205 expression determined the downregulation of ERRFI1 which, in turn, caused EGFR activation, sustaining resistance to MET-TKIs. Anti-miR-205 transduction reverted crizotinib resistance in vivo, while miR-205 over-expression rendered wt cells refractory to TKI treatment. Importantly, in the absence of EGFR genetic alterations, miR-205/ERRFI1-driven EGFR activation rendered MET-TKI-resistant cells sensitive to combined MET/EGFR inhibition. As a proof of concept of the clinical relevance of this new mechanism of adaptive resistance, we report that a patient with a MET-amplified lung adenocarcinoma displayed deregulation of the miR-205/ERRFI1 axis in concomitance with onset of clinical resistance to anti-MET therapy.

Original languageEnglish
JournalEMBO Molecular Medicine
Volume10
Issue number9
DOIs
Publication statusPublished - Sep 2018

Fingerprint

Protein-Tyrosine Kinases
Therapeutics
Neoplasms
Down-Regulation
RNA
Cell Line

Cite this

miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling. / Migliore, Cristina; Morando, Elena; Ghiso, Elena; Anastasi, Sergio; Leoni, Vera P; Apicella, Maria; Cora', Davide; Sapino, Anna; Pietrantonio, Filippo; De Braud, Filippo; Columbano, Amedeo; Segatto, Oreste; Giordano, Silvia.

In: EMBO Molecular Medicine, Vol. 10, No. 9, 09.2018.

Research output: Contribution to journalArticle

@article{646319c70d0947d4bd8b76b114b00611,
title = "miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling",
abstract = "The onset of secondary resistance represents a major limitation to long-term efficacy of target therapies in cancer patients. Thus, the identification of mechanisms mediating secondary resistance is the key to the rational design of therapeutic strategies for resistant patients. MiRNA profiling combined with RNA-Seq in MET-addicted cancer cell lines led us to identify the miR-205/ERRFI1 (ERBB receptor feedback inhibitor-1) axis as a novel mediator of resistance to MET tyrosine kinase inhibitors (TKIs). In cells resistant to MET-TKIs, epigenetically induced miR-205 expression determined the downregulation of ERRFI1 which, in turn, caused EGFR activation, sustaining resistance to MET-TKIs. Anti-miR-205 transduction reverted crizotinib resistance in vivo, while miR-205 over-expression rendered wt cells refractory to TKI treatment. Importantly, in the absence of EGFR genetic alterations, miR-205/ERRFI1-driven EGFR activation rendered MET-TKI-resistant cells sensitive to combined MET/EGFR inhibition. As a proof of concept of the clinical relevance of this new mechanism of adaptive resistance, we report that a patient with a MET-amplified lung adenocarcinoma displayed deregulation of the miR-205/ERRFI1 axis in concomitance with onset of clinical resistance to anti-MET therapy.",
author = "Cristina Migliore and Elena Morando and Elena Ghiso and Sergio Anastasi and Leoni, {Vera P} and Maria Apicella and Davide Cora' and Anna Sapino and Filippo Pietrantonio and {De Braud}, Filippo and Amedeo Columbano and Oreste Segatto and Silvia Giordano",
note = "{\circledC} 2018 The Authors. Published under the terms of the CC BY 4.0 license.",
year = "2018",
month = "9",
doi = "10.15252/emmm.201708746",
language = "English",
volume = "10",
journal = "EMBO Molecular Medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling

AU - Migliore, Cristina

AU - Morando, Elena

AU - Ghiso, Elena

AU - Anastasi, Sergio

AU - Leoni, Vera P

AU - Apicella, Maria

AU - Cora', Davide

AU - Sapino, Anna

AU - Pietrantonio, Filippo

AU - De Braud, Filippo

AU - Columbano, Amedeo

AU - Segatto, Oreste

AU - Giordano, Silvia

N1 - © 2018 The Authors. Published under the terms of the CC BY 4.0 license.

PY - 2018/9

Y1 - 2018/9

N2 - The onset of secondary resistance represents a major limitation to long-term efficacy of target therapies in cancer patients. Thus, the identification of mechanisms mediating secondary resistance is the key to the rational design of therapeutic strategies for resistant patients. MiRNA profiling combined with RNA-Seq in MET-addicted cancer cell lines led us to identify the miR-205/ERRFI1 (ERBB receptor feedback inhibitor-1) axis as a novel mediator of resistance to MET tyrosine kinase inhibitors (TKIs). In cells resistant to MET-TKIs, epigenetically induced miR-205 expression determined the downregulation of ERRFI1 which, in turn, caused EGFR activation, sustaining resistance to MET-TKIs. Anti-miR-205 transduction reverted crizotinib resistance in vivo, while miR-205 over-expression rendered wt cells refractory to TKI treatment. Importantly, in the absence of EGFR genetic alterations, miR-205/ERRFI1-driven EGFR activation rendered MET-TKI-resistant cells sensitive to combined MET/EGFR inhibition. As a proof of concept of the clinical relevance of this new mechanism of adaptive resistance, we report that a patient with a MET-amplified lung adenocarcinoma displayed deregulation of the miR-205/ERRFI1 axis in concomitance with onset of clinical resistance to anti-MET therapy.

AB - The onset of secondary resistance represents a major limitation to long-term efficacy of target therapies in cancer patients. Thus, the identification of mechanisms mediating secondary resistance is the key to the rational design of therapeutic strategies for resistant patients. MiRNA profiling combined with RNA-Seq in MET-addicted cancer cell lines led us to identify the miR-205/ERRFI1 (ERBB receptor feedback inhibitor-1) axis as a novel mediator of resistance to MET tyrosine kinase inhibitors (TKIs). In cells resistant to MET-TKIs, epigenetically induced miR-205 expression determined the downregulation of ERRFI1 which, in turn, caused EGFR activation, sustaining resistance to MET-TKIs. Anti-miR-205 transduction reverted crizotinib resistance in vivo, while miR-205 over-expression rendered wt cells refractory to TKI treatment. Importantly, in the absence of EGFR genetic alterations, miR-205/ERRFI1-driven EGFR activation rendered MET-TKI-resistant cells sensitive to combined MET/EGFR inhibition. As a proof of concept of the clinical relevance of this new mechanism of adaptive resistance, we report that a patient with a MET-amplified lung adenocarcinoma displayed deregulation of the miR-205/ERRFI1 axis in concomitance with onset of clinical resistance to anti-MET therapy.

U2 - 10.15252/emmm.201708746

DO - 10.15252/emmm.201708746

M3 - Article

C2 - 30021798

VL - 10

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

IS - 9

ER -